Uh so Nirsevimab seems pretty good.
publications.aap.org/pediatrics/a...
publications.aap.org/pediatrics/a...
November 5, 2026 at 7:46 PM
Uh so Nirsevimab seems pretty good.
publications.aap.org/pediatrics/a...
publications.aap.org/pediatrics/a...
📊 Among infants in France, nirsevimab was associated with lower rates of hospitalization for #RSV-related lower respiratory tract infection during the first year across 2 consecutive seasons. ja.ma/4jRfQwv
First- and Second-Year Outcomes After Nirsevimab Immunization
This cohort study examines data from nationwide matched cohorts using the French National Health Data System to assess the effectiveness of nirsevimab across 2 respiratory syncytial virus seasons as well as related hospitalizations.
ja.ma
November 6, 2026 at 11:00 AM
📊 Among infants in France, nirsevimab was associated with lower rates of hospitalization for #RSV-related lower respiratory tract infection during the first year across 2 consecutive seasons. ja.ma/4jRfQwv
New #PHRP #EditorsChoice article ⚕️
'Under pressure: lessons learnt from rapid implementation of the respiratory syncytial virus maternal vaccine and infant nirsevimab in Sydney, Australia'
By Isabella Townshend, et al.
Published #OpenAccess: doi.org/10.1071/PU26...
'Under pressure: lessons learnt from rapid implementation of the respiratory syncytial virus maternal vaccine and infant nirsevimab in Sydney, Australia'
By Isabella Townshend, et al.
Published #OpenAccess: doi.org/10.1071/PU26...
November 5, 2026 at 10:50 PM
New #PHRP #EditorsChoice article ⚕️
'Under pressure: lessons learnt from rapid implementation of the respiratory syncytial virus maternal vaccine and infant nirsevimab in Sydney, Australia'
By Isabella Townshend, et al.
Published #OpenAccess: doi.org/10.1071/PU26...
'Under pressure: lessons learnt from rapid implementation of the respiratory syncytial virus maternal vaccine and infant nirsevimab in Sydney, Australia'
By Isabella Townshend, et al.
Published #OpenAccess: doi.org/10.1071/PU26...
The AAFP is dedicated to providing evidence-based RSV vaccine recommendations, so you are equipped to answer patient questions, make a strong recommendation and help protect patients.
Access all of our respiratory recommendations and discover more resources: www.aafp.org/vaccines.
Access all of our respiratory recommendations and discover more resources: www.aafp.org/vaccines.
November 3, 2026 at 7:20 PM
The AAFP is dedicated to providing evidence-based RSV vaccine recommendations, so you are equipped to answer patient questions, make a strong recommendation and help protect patients.
Access all of our respiratory recommendations and discover more resources: www.aafp.org/vaccines.
Access all of our respiratory recommendations and discover more resources: www.aafp.org/vaccines.
Más de 11 mil recién nacidos y lactantes han recibido Nirsevimab en la región. La estrategia busca reducir las infecciones respiratorias graves y las hospitalizaciones infantiles.
Biobío alcanza un 98,8% de cobertura de inmunización contra el virus respiratorio sincicial en recién nacidos
Más de 11 mil recién nacidos y lactantes han recibido Nirsevimab en la región. La estrategia busca reducir las infecciones respiratorias graves y las hospitalizaciones infantiles.
www.latribuna.cl
November 2, 2026 at 8:00 PM
Más de 11 mil recién nacidos y lactantes han recibido Nirsevimab en la región. La estrategia busca reducir las infecciones respiratorias graves y las hospitalizaciones infantiles.
From @idweek.bsky.social 💉
Both infant administration of #nirsevimab and #MaternalImmunization effectively reduced the risk for emergency department visits for #RSV during the first year of life. #IDSky
Both infant administration of #nirsevimab and #MaternalImmunization effectively reduced the risk for emergency department visits for #RSV during the first year of life. #IDSky
Nirsevimab, Maternal Vaccines Protect Infants Against RSV-Related Emergency Visits
Nirsevimab and maternal vaccination each provide substantial protection against RSV in infants requiring emergency care.
www.infectiousdiseaseadvisor.com
October 30, 2026 at 8:14 PM
From @idweek.bsky.social 💉
Both infant administration of #nirsevimab and #MaternalImmunization effectively reduced the risk for emergency department visits for #RSV during the first year of life. #IDSky
Both infant administration of #nirsevimab and #MaternalImmunization effectively reduced the risk for emergency department visits for #RSV during the first year of life. #IDSky
3/3 Maternal Vaccination vs Nirsevimab Use and Respiratory Syncytial Virus Infection Among Full-Term Infants.
JAMA Netw Open · 1 Oct 2026
doi.org/10.1001/jamanetworkopen.2026.36760
JAMA Netw Open · 1 Oct 2026
doi.org/10.1001/jamanetworkopen.2026.36760
October 31, 2026 at 2:26 PM
3/3 Maternal Vaccination vs Nirsevimab Use and Respiratory Syncytial Virus Infection Among Full-Term Infants.
JAMA Netw Open · 1 Oct 2026
doi.org/10.1001/jamanetworkopen.2026.36760
JAMA Netw Open · 1 Oct 2026
doi.org/10.1001/jamanetworkopen.2026.36760
RSV antibodies in infants.
NMA, 18 RCTs, 33,283 infants: severe RSV infection OR 0.08 clesrovimab, 0.12 motavizumab, 0.20 nirsevimab. No mortality difference.
Xiong, Ge et al. Drugs 2026
https://pubmed.ncbi.nlm.nih.gov/42879082/
Weekly papers by topic, free: https://papertis.com
#MedSky #PedSky
NMA, 18 RCTs, 33,283 infants: severe RSV infection OR 0.08 clesrovimab, 0.12 motavizumab, 0.20 nirsevimab. No mortality difference.
Xiong, Ge et al. Drugs 2026
https://pubmed.ncbi.nlm.nih.gov/42879082/
Weekly papers by topic, free: https://papertis.com
#MedSky #PedSky
October 30, 2026 at 2:02 PM
RSV antibodies in infants.
NMA, 18 RCTs, 33,283 infants: severe RSV infection OR 0.08 clesrovimab, 0.12 motavizumab, 0.20 nirsevimab. No mortality difference.
Xiong, Ge et al. Drugs 2026
https://pubmed.ncbi.nlm.nih.gov/42879082/
Weekly papers by topic, free: https://papertis.com
#MedSky #PedSky
NMA, 18 RCTs, 33,283 infants: severe RSV infection OR 0.08 clesrovimab, 0.12 motavizumab, 0.20 nirsevimab. No mortality difference.
Xiong, Ge et al. Drugs 2026
https://pubmed.ncbi.nlm.nih.gov/42879082/
Weekly papers by topic, free: https://papertis.com
#MedSky #PedSky
#Maternal #Vaccination vs #Nirsevimab Use and #Respiratory #Syncytial #Virus Infection Among Full-Term Infants. Open Access. ivancevichmd.blogspo...
October 26, 2026 at 2:19 PM
#Maternal #Vaccination vs #Nirsevimab Use and #Respiratory #Syncytial #Virus Infection Among Full-Term Infants. Open Access. ivancevichmd.blogspo...
Interesting review suggesting effective RSV protection/prevention won't end bronchiolitis in infants and young children
link.springer.com/article/10.1...
And while I agree, my strong expectation is that severe bronchiolitis cases will go right down in infants with vaccinated mothers.
link.springer.com/article/10.1...
And while I agree, my strong expectation is that severe bronchiolitis cases will go right down in infants with vaccinated mothers.
Beyond RSV: why the bronchiolitis burden in infants will not simply disappear - European Journal of Pediatrics
Nirsevimab and maternal respiratory syncytial virus (RSV) vaccination are delivering real-world important reductions in RSV-bronchiolitis hospitalisations, a landmark achievement in paediatric prevent...
link.springer.com
October 26, 2026 at 11:53 AM
Interesting review suggesting effective RSV protection/prevention won't end bronchiolitis in infants and young children
link.springer.com/article/10.1...
And while I agree, my strong expectation is that severe bronchiolitis cases will go right down in infants with vaccinated mothers.
link.springer.com/article/10.1...
And while I agree, my strong expectation is that severe bronchiolitis cases will go right down in infants with vaccinated mothers.
Un estudio sobre mensajes telefónicos e inmunización de bebés con nirsevimab, el anticuerpo contra el VRS, ganó un premio en el III Congreso de Salud Pública de la UNI, en Encarnación. Este año ya lo recibieron más de 40.000 bebés. buff.ly/R5yMxUQ
October 25, 2026 at 1:03 PM
Un estudio sobre mensajes telefónicos e inmunización de bebés con nirsevimab, el anticuerpo contra el VRS, ganó un premio en el III Congreso de Salud Pública de la UNI, en Encarnación. Este año ya lo recibieron más de 40.000 bebés. buff.ly/R5yMxUQ
Real-world data backed the effectiveness of second-season nirsevimab (Beyfortus) immunizations against hospitalizations for children at high risk for severe RSV illness. #IDWeek2026 @idweek.bsky.social
https://www.medpagetoday.com/meetingcoverage/idweek/123536
https://www.medpagetoday.com/meetingcoverage/idweek/123536
Second-Season RSV Immunization Worked for Eligible Children
U.S. study reports 75% effectiveness against RSV-associated hospitalization in the second season
www.medpagetoday.com
October 23, 2026 at 5:36 PM
Real-world data backed the effectiveness of second-season nirsevimab (Beyfortus) immunizations against hospitalizations for children at high risk for severe RSV illness. #IDWeek2026 @idweek.bsky.social
https://www.medpagetoday.com/meetingcoverage/idweek/123536
https://www.medpagetoday.com/meetingcoverage/idweek/123536
Australia recommends national infant access to nirsevimab—but price questions remain. https://www.mattheneus.com/editorial/pbac-nirsevimab-national-immunisation-program-access-price-conditions-2026-10-16 #HTA #Pharma #RegulatoryAffairs
October 18, 2026 at 8:04 PM
Australia recommends national infant access to nirsevimab—but price questions remain. https://www.mattheneus.com/editorial/pbac-nirsevimab-national-immunisation-program-access-price-conditions-2026-10-16 #HTA #Pharma #RegulatoryAffairs
Have your pregnant patients asked how to protect their baby from RSV? New CDC data in Pediatrics: maternal RSV vaccination was 82% effective and nirsevimab 77% effective against infant RSV hospitalization in 2024 to 2025. #AII doi.org/10.1542/peds...
October 19, 2026 at 2:03 PM
Have your pregnant patients asked how to protect their baby from RSV? New CDC data in Pediatrics: maternal RSV vaccination was 82% effective and nirsevimab 77% effective against infant RSV hospitalization in 2024 to 2025. #AII doi.org/10.1542/peds...
Estudos en Galicia e Andalucía avalan a protección fronte ao VRS e os beneficios da vacina antigripal de alta dose
Estudos en Galicia e Andalucía avalan a protección fronte ao VRS e os beneficios da vacina antigripal de alta dose
As investigacións presentadas no congreso de vacinoloxía de Vigo mostran menos ingresos de lactantes tras a inmunización con nirsevimab e unha maior protección das persoas maiores coa vacina ...
www.galiciaconfidencial.com
October 19, 2026 at 11:49 AM
Estudos en Galicia e Andalucía avalan a protección fronte ao VRS e os beneficios da vacina antigripal de alta dose
Among 1,942 infant encounters in Canada, nirsevimab effectiveness was estimated at 77% against RSV-related ED visits, 79% against hospitalisation and 97% against ICU admission. Test-negative case-control study. #RSV #Pediatrics
doi.org/10.1001/jama...
doi.org/10.1001/jama...
October 17, 2026 at 4:30 PM
Among 1,942 infant encounters in Canada, nirsevimab effectiveness was estimated at 77% against RSV-related ED visits, 79% against hospitalisation and 97% against ICU admission. Test-negative case-control study. #RSV #Pediatrics
doi.org/10.1001/jama...
doi.org/10.1001/jama...
🫁 Protección frente al #VRS en Castilla y León:
👶 Nirsevimab para nacidos entre 1/4/2026 y 31/3/2027.
👵 Vacunación en adultos con determinados riesgos graves e institucionalizados no vacunados.
⚠️ La vacuna del adulto no es anual.
📍 Zamora: 1.040 dosis infantiles + 2.000 para adultos.
👶 Nirsevimab para nacidos entre 1/4/2026 y 31/3/2027.
👵 Vacunación en adultos con determinados riesgos graves e institucionalizados no vacunados.
⚠️ La vacuna del adulto no es anual.
📍 Zamora: 1.040 dosis infantiles + 2.000 para adultos.
October 15, 2026 at 7:01 AM
🫁 Protección frente al #VRS en Castilla y León:
👶 Nirsevimab para nacidos entre 1/4/2026 y 31/3/2027.
👵 Vacunación en adultos con determinados riesgos graves e institucionalizados no vacunados.
⚠️ La vacuna del adulto no es anual.
📍 Zamora: 1.040 dosis infantiles + 2.000 para adultos.
👶 Nirsevimab para nacidos entre 1/4/2026 y 31/3/2027.
👵 Vacunación en adultos con determinados riesgos graves e institucionalizados no vacunados.
⚠️ La vacuna del adulto no es anual.
📍 Zamora: 1.040 dosis infantiles + 2.000 para adultos.
New Personal View
Second-season observations after prophylaxis in the evaluation of the impact of nirsevimab in Galicia (NIRSE-GAL) study: mechanistic interpretation and implications for respiratory syncytial virus prevention strategy
www.thelancet.com/journals/lan...
Second-season observations after prophylaxis in the evaluation of the impact of nirsevimab in Galicia (NIRSE-GAL) study: mechanistic interpretation and implications for respiratory syncytial virus prevention strategy
www.thelancet.com/journals/lan...
Second-season observations after prophylaxis in the evaluation of the impact of nirsevimab in Galicia (NIRSE-GAL) study: mechanistic interpretation and implications for respiratory syncytial virus pre...
The evaluation of the impact of nirsevimab in Galicia (NIRSE-GAL) study reported that
universal infant nirsevimab prophylaxis was associated with a substantial reduction
in respiratory syncytial virus...
www.thelancet.com
October 14, 2026 at 7:09 AM
New Personal View
Second-season observations after prophylaxis in the evaluation of the impact of nirsevimab in Galicia (NIRSE-GAL) study: mechanistic interpretation and implications for respiratory syncytial virus prevention strategy
www.thelancet.com/journals/lan...
Second-season observations after prophylaxis in the evaluation of the impact of nirsevimab in Galicia (NIRSE-GAL) study: mechanistic interpretation and implications for respiratory syncytial virus prevention strategy
www.thelancet.com/journals/lan...
🩺 ¿Tu bebé nació entre abril y septiembre? En octubre le toca. Guía con fuentes oficiales: https://www.guarderiadreams.es/materiales/bronquiolitis-nirsevimab-la-rioja.php
October 13, 2026 at 8:06 AM
🩺 ¿Tu bebé nació entre abril y septiembre? En octubre le toca. Guía con fuentes oficiales: https://www.guarderiadreams.es/materiales/bronquiolitis-nirsevimab-la-rioja.php
Muchas familias descubren la bronquiolitis en plena noche. ¿A tu bebé le pusieron el nirsevimab al nacer o al empezar el otoño?
October 11, 2026 at 1:32 AM
Muchas familias descubren la bronquiolitis en plena noche. ¿A tu bebé le pusieron el nirsevimab al nacer o al empezar el otoño?
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
La provincia no registró muertes por VRS en menores de un año durante el invierno de 2026. Cómo fue el plan que combinó vacuna para embarazadas y nirsevimab para recién nacidos y lactantes sin protección materna
dlvr.it
October 8, 2026 at 10:06 PM
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
La provincia no registró muertes por VRS en menores de un año durante el invierno de 2026. Cómo fue el plan que combinó vacuna para embarazadas y nirsevimab para recién nacidos y lactantes sin protección materna
dlvr.it
October 8, 2026 at 10:11 PM
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
La provincia no registró muertes por VRS en menores de un año durante el invierno de 2026. Cómo fue el plan que combinó vacuna para embarazadas y nirsevimab para recién nacidos y lactantes sin protección materna
dlvr.it
October 8, 2026 at 10:10 PM
Una nueva estrategia contra el virus sincicial respiratorio redujo 73% las internaciones de bebés en Córdoba
Nirsevimab cut antibiotic use in infants by 14.4% for ARTIs, 40.3% for bronchiolitis, & 69.4% for RSV hospitalizations among 15,341 infants. 🧴👶📉
The Effectiveness of Nirsevimab on Antibiotic Use in Children Using Target Trial Emulation
Nirsevimab is a monoclonal antibody with demonstrated efficacy in preventing respiratory syncytial virus (RSV) infections in infants. Because acute respiratory tract infections (ARTIs), including viral infections, often lead to antibiotic prescribing, we aimed to determine the effectiveness of nirsevimab on antibiotic prescribing among infants with medically attended ARTIs.MethodsA primary care attendee cohort was established using electronic health record data from 32 diverse practices across a healthcare network to emulate a target trial comparing nirsevimab to no treatment among infants <8 months. Eligible infants were seen at a primary care practice within 14 days of life. Primary outcomes included time to first antibiotic prescription for (1) outpatient ARTIs, (2) outpatient encounters for bronchiolitis, and (3) RSV-related hospitalizations. Nirsevimab effectiveness was calculated as 1 minus the risk ratio for each primary outcome.ResultsAmong 15 341 patients who met inclusion criteria, 7413 received nirsevimab. Compared with no treatment, nirsevimab administration led to a 14.4% (95% CI: 7.8%, 20.6%) reduction in antibiotic prescribing for outpatient ARTIs, a 40.3% (95% CI: 25.1%, 52.5%) reduction in antibiotic prescribing for outpatient bronchiolitis, and a 69.4% (95% CI: 4.8%, 90.1%) reduction in antibiotic prescribing for RSV-related hospitalizations.ConclusionsNirsevimab administration in primary care reduced antibiotic use for ARTIs in both ambulatory and inpatient settings.
academic.oup.com
October 7, 2026 at 11:00 PM
Nirsevimab cut antibiotic use in infants by 14.4% for ARTIs, 40.3% for bronchiolitis, & 69.4% for RSV hospitalizations among 15,341 infants. 🧴👶📉